Pembrolizumab plus chemo with surgery for pleural mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a consent form and are willing to join the study.
- You’re at least 18 years old.
- Your cancer can be measured on scans (it must meet the study’s “measurable disease” rules).
- You can provide a fresh tumor tissue sample from a biopsy taken up to 6 weeks before treatment starts.
- Your general health is good enough to do study treatment (performance status 0 or 1).
- Your organ tests (such as blood counts and liver/kidney function) are acceptable, done within 10 days of starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
This trial tests adding a drug called fianlimab to another drug (cemiplimab) plus chemotherapy for people with a type of lung cancer called pleural mesothelioma. It aims to see if the combination is more effective than cemiplimab plus chemo alone.
This trial tests whether adding cadonilimab (an immune treatment) and bevacizumab (a medicine that targets blood supply to tumors) to standard chemotherapy can control pleural malignant mesothelioma that cannot be removed with surgery. It’s meant for people who have not yet started medicine for advanced disease and who meet health and blood test requirements.
Hear when a new Mesotheliomas Pleural trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.